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Abstract
Background: Several treatments are available for actinic keratosis (AK) on the face and scalp. Most treatment modalities
were compared to placebo and therefore little is known on their relative efficacy.
Objectives: To compare the different treatments for mild to moderate AK on the face and scalp available in clinical practice
in Europe.
Methods: A network meta-analysis (NMA) was performed on the outcome ‘‘complete patient clearance’’. Ten treatment
modalities were included: two 5-aminolaevulinic acid photodynamic therapies (ALA-PDT), applied as gel (BF-200 ALA) or
patch; methyl-aminolevulinate photodynamic therapy (MAL-PDT); three modalities with imiquimod (IMI), applied as a 4-
week or 16-week course with 5% imiquimod, or a 2–3 week course with 3.75% imiquimod; cryotherapy; diclofenac 3% in
2.5% hyaluronic acid; 0.5% 5-fluorouracil (5-FU); and ingenol mebutate (IMB). The only data available for 5% 5-FU was from
one small study and was determined to be too limited to be reliably included in the analysis. For BF-200 ALA and MAL-PDT,
data from illumination with narrow-band lights were selected as these are typically used in clinical practice. The NMA was
performed with a random-effects Bayesian model.
Results: 25 trials on 5,562 patients were included in the NMA. All active treatments were significantly better than placebo.
BF-200 ALA showed the highest efficacy compared to placebo to achieve total patient clearance. BF-200 ALA had the
highest probability to be the best treatment and the highest SUCRA score (64.8% and 92.1%), followed by IMI 5% 4 weeks
(10.1% and 74.2%) and 5-FU 0.5% (7.2% and 66.8%).
Conclusions: This NMA showed that BF-200 ALA, using narrow-band lights, was the most efficacious treatment for mild to
moderate AK on the face and scalp. This analysis is relevant for clinical decision making and health technology assessment,
assisting the improved management of AK.
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Actinic keratosis (AK) is a premalignant skin condition,
characterised by thick, scaly, or crusty patches on the skin. The
lesions can be located on the face, ears, neck, scalp, chest, hands,
forearms, or lips. A common synonym of actinic keratosis is solar
keratosis, as it is predominantly caused by prolonged and
unprotected exposure to sunlight. Male gender, older age, light
pigmentation status (Fitzpatrick skin types I and II), baldness, skin
wrinkling, and extensive history for sunburn are risk factors for AK
[1]. AK is considered as a pre-cancerous condition, since there is a
continuous annual risk of lesions progressing to squamous cell
carcinoma (SCC). In various epidemiological studies the risk for
progression from AK to SCC has been estimated between nil and
0.53% per lesion per year [2–4]. Over 10 to 25 years, the
estimated progression from AK to SCC has been estimated
between 5% and 20% [5]. AK is one of the most common
conditions treated by dermatologists (third most common reason
for consulting a dermatologist [6]) and progression to SCC can
impact on patient health related quality of life (HRQoL) [7]. The
primary goal of AK treatment is to achieve complete clearance of
lesions, thereby eliminating the risk of progression to SCC. The
removal of visible lesions may additionally improve patient
HRQoL [8,9]. Available AK treatments used in clinical practice
include topical treatments (such as diclofenac (DCF); 5-fluoroura-
cil (5-FU), imiquimod (IMI), ingenol mebutate (IMB)), cryother-
apy, and photodynamic therapy (PDT) using alternative photo-
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sensitizing agents including 5-aminolaevulinic acid (ALA) or
methyl aminolevulinate (MAL).
When comparing the effectiveness of two or more interventions,
randomized clinical trials (RCTs) that compare the interventions
directly (head-to-head trials) are often preferred for health
technology assessment and reimbursement decision making. In
AK, most but not all published trials are placebo-controlled
studies, limiting the potential to compare active treatments.
Network meta-analyses (NMA), can provide a valid statistical
estimate of the comparative efficacy of different treatment
modalities by combining in a network of evidence both direct
head-to-head and indirect comparative evidence [10–13]. A NMA
of different treatments in AK has recently been published [14].
This study was performed as part of a Cochrane Review [15]. The
NMA however grouped all the ALA-PDT and different imiqui-
mod (IMI) treatments. Therefore, to increase the value for clinical
and reimbursement decision making purposes the objective of this
study was to perform a Bayesian NMA in order to provide the
most up to date assessment of the comparative efficacy of available
treatment modalities for mild to moderate AK on the face or scalp,
including different treatment modalities with ALA-PDT and
imiquimod. The NMA will be performed from a European
perspective, thereby focusing on treatments available and regularly
used in clinical practice in Europe. The starting point for our
NMA was to utilise the studies identified in the recent Cochrane
Review of AK treatments [15]. Results from this NMA may be
used as the source of clinical efficacy data in economic evaluations
of the cost-effectiveness of AK treatments.
Methods
Study selection
The recent Cochrane systematic search and review was used to
identify studies on treatments for AK, provide information on
literature search strategies and on the risk of bias for the included
studies.15 In the Cochrane review, databases were searched up to
March 2011; a final prepublication search was performed in April
2012 but these were not described in the Cochrane review (these
studies were listed as ‘awaiting classification’). The Cochrane
review included 83 studies; 12 studies were listed as ‘awaiting
classification’; and several on-going studies were identified. The
studies included in the Cochrane review and the studies awaiting
classification were assessed for inclusion in the NMA; furthermore,
the status of the ongoing studies was also reassessed in January
2014. No new systematic literature review was performed, but
extensive literature searches by the authors did not result in new
trials being identified. Two dermatology consultants reviewed the
inclusion and exclusion criteria for the clinical trials and the design
of the NMA (see Acknowledgement section). Both authors checked
the studies identified in the Cochrane NMA for inclusion in our
updated NMA, in order to ensure the studies included were
comparable in terms of study design, treatment modality studied
and patient characteristics. Any disagreements regarding study
selection were resolved by consensus. Both published and
unpublished randomized controlled trials (RCT’s) were considered
for inclusion. RCT’s using intra-individual designs (e.g. treatments
applied to opposite sides of the face) were excluded. Studies
needed to report intention to treat (ITT) or full analysis set (FAS)
data, not only per-protocol (PP) data. Evaluation of efficacy
needed to be a minimum of one month after the end of treatment,
(EOT) but no more than 1 year post-treatment.
Types of participants and treatments
Studies on participants with mild to moderate AK on the face or
scalp were included, defined as having between 5 and 20 lesions.
Studies with immunosuppressed participants were excluded.
Studies on combination therapies were excluded, as the focus of
the NMA was on the efficacy of the individual treatment options.
Trials studying dose variations of a single treatment (e.g. dose-
ranging studies) or unconventional treatment dosages or schedules
(e.g. 3- or 8-week courses of IMI 5%) were also excluded as these
could not be included in a treatment network. However, small
differences in treatment dosages or schedules were considered to
be equivalent, such as IMI 5% applied 2 or 3 times per week. The
present analysis was performed from a European clinical practice
perspective; trials on ALA stick [16] were excluded as this
treatment is not available in Europe. However, this treatment was
included in a scenario analysis enabling the assessment of its
relative efficacy. For trials with BF-200 ALA and MAL-PDT,
efficacy data using narrow-band light sources (LED lights) were
used [17–20], as narrow-band lights are the standard light source
typically used in clinical practice.
Eleven treatment modalities were included in the NMA: three
modalities with 5-aminolaevulinic acid (ALA)-photodynamic
therapy (PDT), applied as a gel or patch; methyl aminolaevulinate
(MAL)-PDT; three modalities with imiquimod (IMI), applied as a
4-week course with 5% IMI, a 16-week course of 5% IMI or a 2–3
week course with IMI 3.75%; cryotherapy; diclofenac 3% in 2.5%
hyaluronic acid (DCF); 0.5% 5-fluorouracil (5-FU); and ingenol
mebutate (IMB). All vehicle and placebo treatment arms,
including placebo-PDT, were considered to be equivalent and
were treated as a single arm in the NMA. Treatment with 5% 5-
fluorouracil (5-FU) was also considered. However, because the
only included study [21] with this treatment was very small and
reported a clearance rate (23 out of 24 patients) that was not
consistent with the literature [22], this treatment was not included
in the NMA.
Outcome measures
In line with the Cochrane review, the primary read-out
considered was ‘complete patient clearance’, i.e. total clearance
of all of a patient’s lesions. Studies that reported only other
outcomes, such as number of lesions cleared or partial participant
clearance, were not included. For treatments that allowed for
multiple treatment courses, including MAL-PDT, BF-200 ALA
and IMI 5% 4-week course, the clearance rates after the (optional)
second course were used in the NMA. Both target-lesion and all-
lesion studies were included but for studies presenting both
outcomes only the all-lesions outcome was used in the NMA.
Network meta-analysis
A Bayesian random-effects NMA for multi-arm trials based on
the model provided by the University of Bristol in the UK [23] was
used to analyse the efficacy of all treatments in the network
simultaneously. A fixed-effects model was considered but the
model fit of the random-effects model was considerably better
based on Deviance Information Criteria (DIC) and residual
deviance statistics. Three chains with 10,000 iterations and a burn-
in of 2000 iterations were run using non-informative priors. The
main outcome parameter of the NMA was the probability to
achieve total patient clearance, expressed in log OR relative to the
other treatments or placebo. The patient clearance rates were also
calculated for each treatment. The estimated treatment effect size
and associated uncertainty was translated into the probability that
a certain treatment was the ‘best’ (i.e. most effective treatment). An
alternative ranking method, the surface under the cumulative
Efficacy of Actinic Keratosis Treatments
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ranking curve (SUCRA), was also calculated. SUCRA ranges from
0 to 1, where 1 reflects the best treatment with no uncertainty and
0 reflects the worst treatment with no uncertainty [24]. Inconsis-
tency between direct and indirect evidence in the NMA was
estimated as the weighted difference between the indirect and
direct estimate for a randomly chosen contrast, using the package
‘MTcoherence.fun’ [25]. The program Winbugs 1.4 statistical
software (MRC Biostatistics Unit, Cambridge, UK) was used for
the NMA.
In addition to the NMA, simple weighted averages for complete
patient clearance were calculated per treatment arm; (i.e. the
number of patients with complete patient clearance divided by the
total number of patients) with 95% confidence intervals calculated
by assuming binomial distributions. The results from this naı¨ve
meta-analysis were compared to the results from the NMA. Linear
regression analyses were performed to test for associations between
patient characteristics, reported on trial level, and patient
complete clearance in the placebo arms of the included studies.
Fixed-effects (FE) and random-effects (RE) direct meta-analyses
were performed for all studies comparisons. Tests for heterogene-
ity were performed but as a default the results from the random-
effects models were reported where available to allow for
heterogeneity in the studies included. The program R 3.0.1




The studies included in the Cochrane review were indepen-
dently assessed for suitability for inclusion in the NMA. An
overview of the selection process is shown in Fig. 1. Reasons for
study exclusion from the NMA were that they did not report the
outcome ‘complete patient clearance’ (36 studies); did not fit in a
treatment network (6 studies); were for the wrong indication (4
studies in immunocompromised patients; 6 studies not for mild to
moderate AK on face or scalp); or for various other reasons such as
an intra-individual study design or treatment with combination
therapy. A detailed overview of study exclusion criteria is shown in
Table S1. A total of 25 studies were available for inclusion in the
NMA.
Trial and patient characteristics
An overview of the included studies and patient characteristics is
shown in Table 1. Most included studies were placebo-controlled
studies, only 1 study compared only active treatments.28 The trials
included a total of 5,562 AK patients. The average patient age in
the studies ranged from 63.2 to 71.9 years; the majority (81.4%)
were male. The average number of lesions per patients varied
from 5.6 to 15.5. Olsen scores (AK lesion severity) and Fitzpatrick
skin types were not reported in most studies (15 and 11 studies,
respectively). The patient characteristics were similar between the
interventions. In univariate or multivariate linear regression
analyses, there were no significant associations between complete
patient clearance and age, gender, number of lesions at baseline,
Olsen score or Fitzpatrick skin type.
Treatment network
The treatment network for the NMA is shown in Fig. 2. Placebo
treatment was a common reference comparator for all treatment
arms but there were also several active treatment comparisons
(direct head-to-head evidence) that could be included in the
network. The number of patients treated with each therapy is
shown in Table 2. Most patients were treated with Imiquimod
(N = 1,566, with 966 of these receiving IMI 5% 16-weeks),
followed by DCF (N = 413) and IMB (N = 309).
Network meta-analysis results
The NMA model converged and there were no significant
inconsistencies between the direct and indirect evidence within the
NMA. The estimated absolute clearance rates calculated from the
NMA are shown in Table 2 and Figure 3. BF-200 ALA had the
highest absolute complete clearance rate at 75.8% (95% CI: 55.4–
96.2%), followed by 5-FU (59.9%, 95% CI: 38.9–80.9%),
Imiquimod 16 weeks (63.3%, 95% CI: 45.5–81.1%), Imiquimod
4 weeks (56.3%, 95% CI: 33.8–78.8%) and ALA-PDT patch
(56.8%, 95% CI: 30.5–82.1%) (Table 2). The findings were similar
using a naı¨ve meta-analysis approach, although there were some
modest differences in absolute estimates (Table 2). Figure 3 shows
the probabilities for each treatment to be the best (i.e. most
effective) treatment in yellow dots while the SUCRA scores are
shown in yellow squares. BF-200 ALA had the highest probability
(64.8%) to be the most effective treatment, followed by Imiquimod
16 weeks (10.1%) and 5-FU 0.5% (7.2%). The ranking was similar
when using SUCRA scores, being highest for BF-200 ALA
(92.1%), followed by Imiquimod 16 weeks (74.2%) and 5-FU 0.5%
(66.8%).
The results of the NMA and naı¨ve meta-analysis in terms of
Odds Ratios (OR) for complete clearance for each treatment vs.
placebo are presented in Table 3. More extensive results for the
relative efficacies of all included treatments is presented in Table 4.
All active treatments in the analysis were significantly superior to
placebo. BF-200 ALA was associated with an estimated OR of
45.9 (95% CI: 13.9–151.8), followed by IMI 5% 16-week, OR:
23.8 (10.4–54.2) and 5-FU 0.5%, OR: 20.7 (7.7–55.7).
In a sensitivity analysis, ALA-PDT stick was also included in the
analyses, resulting in one additional study being added to the
NMA [16]. Efficacy of the other treatments were not affected by
inclusion of this treatment in the NMA. The highest ranking of
treatments according to the SUCRA scores was BF-200 ALA
(90.8%), followed by IMI 5% 16-week (71.7%), ALA-PDT stick
(69.0%) and 5-FU 0.5% (64.1%). Thus, the efficacy of ALA-PDT
stick was ranked below BF-200 ALA and between IMI 5% 16-
week and 5-FU 0.5%.
Discussion
In this study we performed a network meta-analysis to compare
the efficacy of available treatments for mild to moderate AK on
the face or scalp. The starting point for this analysis was the recent
Cochrane review of AK treatments by exploring the relative effect
of different PDT treatments, and also different imiquimod
preparations. However, we went beyond the Cochrane review
[15] and the related NMA publication by Gupta et al [14] to
include assessment of the relative efficacies of the separate PDT
and imiquimod agents. All treatments showed statistically signif-
icant efficacy compared to placebo. BF-200 ALA gel was the most
efficacious treatment in terms of complete patient clearance, and
also had the highest probability to be the most efficacious
treatment among all compared treatments. The SUCRA scores
also indicated that BF-200 was the most efficacious treatment. As
our study was performed from a European perspective, ALA-PDT
stick treatment was not included in our main analysis. However, a
scenario analysis showed that this treatment could be the second
most effective AK treatment in regions where it is available.
Efficacy of Actinic Keratosis Treatments
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Strengths of the study
NMAs provide a valid statistical alternative to direct head-to-
head studies [10,11]. An advantage of Bayesian NMAs such as this
study over frequentist approaches is the ability to ‘rank’
treatments, either according to probabilities to be the ‘best’ (i.e.
most effective) treatment or according to SUCRA scores, which
can be useful for clinical treatment decisions and HTA [12,13,24].
In a NMA evidence of multiple RCT’s can be combined while
retaining the randomisation element of these trials. This is
opposed to ‘naı¨ve’ meta-analysis, where efficacy data from
individual study arms is extracted and pooled as if they were
from one large trial. Such pooling approaches may lead to biased
efficacy estimates.
The NMA studied the outcome ‘complete patient clearance’.
Although other outcome parameters have been reported in various
RCT’s, such as ‘% reduction in lesion count’, a patient-based
measure was preferred because it can be used in health-economic
analyses.
The studies considered for inclusion in the NMA were identified
in a prior Cochrane review, which used a robust and systematic
approach to identify RCT’s of interventions for actinic keratosis
[15]. Not all studies identified in the Cochrane review were
included in our NMA due to our stricter inclusion criteria. For
example, we only included studies that evaluated efficacy after a
minimum of one month after EOT; this excluded a study that
evaluated efficacy immediately at EOT [26]. We also excluded
studies with unconventional treatment dosages or schedules, such
as 3- or 8-week courses of IMI 5% or a 1-week course of 5-FU
[27], because the focus of this study was in comparing and ranking
AK treatments that are commonly used in clinical practice in
European countries. The efficacy data was extracted from the
published manuscripts of the included studies and not from the
Cochrane review.
The included studies were similar with regard to average age,
gender, number of lesions at baseline and other patient
characteristics. Moreover, patient characteristics were not signif-
icantly correlated with treatment success. This limits the potential
of heterogeneity across trials and consequent bias in the NMA.
Limitations of the study
The results of this study are subject to several limitations.
Although over 5,500 patients were included in the NMA, as in
many NMAs the study was limited by the relatively small number
of trials. Study covariates were not taken into account in the NMA
but were relatively similar across trials; furthermore, there were no
significant associations between patient characteristics in the
different trials and treatment outcome.
Although a random effects model was used for the NMA, which
takes into account study heterogeneity, any differences in trial
procedures and settings between the included studies may have
influenced results. One area of differences in trial design was the
time point of efficacy evaluation. The evaluation time point varied
from 4 weeks after EOT (e.g. all IMI 5% 4 week trials), to 8 weeks
after EOT (e.g. all IMI 5% 16 week trials) and 12 weeks after EOT
(all PDT trials). The influence of these variations in trial design was
limited by excluding trials that evaluated efficacy earlier than one
Figure 1. Flow-chart of study selection.
doi:10.1371/journal.pone.0096829.g001
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month after EOT, because several studies noted a considerable
increase in efficacy between the end of treatment visit and post-
end of treatment visits [28–30].
A limitation of the cryotherapy arm in the NMA was that one of
the two included studies used only one treatment session [31],
whereas in the other study a second cryotherapy session was
allowed although how many patients received a second session was
not reported [21].
Concerns have been voiced that differences in placebo and
vehicle efficacy might limit the validity of grouping vehicle arms in
meta-analyses of AK treatments. The NMA assumes identical
placebo efficacy. However, the hyaluronic acid (HA) vehicle used
in DHA treatment has previously been discussed with respect to
contributing to an enhanced efficacy for placebo [32]. HA
enhances the retention and localization of DHA in the epidermis
and thereby has a permissive or potentiating effect on AK
clearance by DCH [33]. It is unclear whether HA functions only
as a drug delivery system or whether HA alone also influences AK
lesion clearance. In in vitro experiments on colon-26 adenocarci-
nomas, HA alone appeared to have a small effect on tumour
angiogenesis and growth but no effects on cell proliferation or
viability [34]. Other studies confirm that the effects of HA alone
on tumour angiogenesis are small and unsustained compared to
DCH [35]. In animal models, HA alone did not affect vascularity
in granulomatous tissue neovasculature (whereas HA with DHA
did significantly reduce vascularity) [36], or on cholesteatoma
formation in squamous epithelium [37]. Studies on the effective-
ness of HA alone on AK lesion clearance however are lacking.
Similar arguments may be presented for PDT, where, for the
MAL cream and ALA gel studies, lesion preparation in the studies
included mild curettage also in the placebo arms, which by itself
may have some efficacy [17–20]. Therefore, a slight efficacy of the
placebo treatment because of curettage may have caused an
underestimation of the true effectiveness of the active treatments in
these studies.
The absolute clearance as estimated from the NMA generally
corresponded to those in the naı¨ve meta-analysis. However, for
IMB and IMI 5% (16-week course) the estimated absolute
clearance was higher using the NMA compared to the naı¨ve
analysis. This was caused by the relatively low placebo response
rates in the clinical trials of these drugs [38–40]. In general, results
of the NMA were accompanied by large variances. Uncertainty in
the analysis can be reduced when more studies are performed on
the different AK treatments, preferably also including more head-
to-head trials of active treatments.
Discussion of previous studies
Recently, a NMA of treatments in AK based on the Cochrane
review was published [14]. This NMA grouped different ALA-
PDT treatments, such as ALA applied as a gel, a patch or with a
stick. The NMA also grouped different imiquimod treatments and
did not include IMI 3.75%. In clinical practice however, these
drugs are considered as distinct treatment modalities and are
marketed as such [41,42]. The study also included treatment
options that are not available in European clinical practice, such as
ALA stick. The published NMA concluded that 5-FU 5.0% was
the most efficacious treatment, followed by ALA-PDT. Differences
between the NMA from Gupta et al and our NMA may be caused
because our study focused on AK on face or scalp and considered
different ALA-PDT options as separate treatment modalities as
Figure 2. Treatment network for the NMA.
doi:10.1371/journal.pone.0096829.g002
Table 2. Number of patients per treatment, naı¨ve (averaged) clearance rates and clearance rates calculated with NMA.
Number of studies Number of patients Clearance rate
Naı¨ve meta-analysis* NMA{
Placebo 23 2250 6.9% (5.9–8.0%) 6.9% (5.5–8.3%)
MAL-PDT 3 232 65.9% (59.9–72.0%) 54.8% (33.6–76.0%)
BF-200 ALA 2 156 85.3% (79.5–90.4%) 75.8% (55.4–96.2%)
ALA-PDT patch 2 205 62.0% (55.1–68.3%) 56.8% (30.5–83.1%)
Cryotherapy 2 169 49.1% (41.4–56.8%) 38.2% (12.1–64.3%)
Imiquimod 5% (16 weeks) 5 966 45.1% (42.0–48.2%) 63.3% (45.5–81.1%)
Imiquimod 5% (4 weeks) 3 278 57.2% (51.4–62.9%) 56.3% (33.8–78.8%)
Diclofenac 3% 5 413 35.4% (30.8–40.0%) 24.7% (12.4–37.0%)
5-FU 0.5% 3 262 54.6% (48.5–60.7%) 59.9% (38.9–80.9%)
Ingenol mebutate 2 309 43.0% (37.5–48.5%) 54.5% (27.8–81.2%)
Imiquimod 3.75% (4 weeks) 2 322 34.8% (29.5–40.1%) 39.9% (15.6–64.2%)
* calculated by dividing the number of patients with the outcome ‘complete patient clearance’ by the total number of patients for each treatment.
{calculated by applying the relative efficacies output from the NMA to the average clearance rate in the placebo treated patients.
ALA: 5-aminolaevulinic acid; MAL: methyl aminolaevulinate; PDT: photodynamic therapy; 5-FU: 5-Fluorouracil; NMA: Network meta-analysis.
doi:10.1371/journal.pone.0096829.t002
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well as different IMI treatments. Due to limitations in data
availability our NMA was unable to make a reliable estimation of
the efficacy of 5-FU 5.0% and therefore did not include this
treatment. Furthermore, our NMA focused on ALA-PDT using
narrow-band light sources (LED lights) only. Broad-band light
sources have been shown to result in reduced treatment success
[19,20]. Therefore, narrow-band lamps seem to be most relevant
for clinical and HTA decision making.
Several previous studies have performed meta-analyses or
indirect comparisons of AK treatments. Some of these were
narrative [43] or naı¨ve meta-analyses [22] which are open to risk
of bias [44]. Two studies performed meta-analyses of placebo-
controlled studies of IMI 5% (16-week course) [45,46]. These
studies used fixed-effect models but the results were similar to the
random-effects direct meta-analysis in our study. Two studies
performed meta-analyses as part of a pharmacoeconomic evalu-
ation [47–49]. Two economic evaluations performed naı¨ve meta-
analyses [47,49]. A more recent cost-effectiveness study performed
an indirect comparison of IMI 5% (4-week course) and MAL-
PDT, using cryotherapy as the common comparator [48]. This
comparison however included studies with intra-individual ran-
domization [50] and the treatment outcome ‘complete lesion
clearance’ rather than ‘complete patient clearance’ [50,51]. Our
analysis excluded these types of studies.
Implications for clinicians and policymakers
The results of this study may provide valuable information for
the optimal management of AK and for use in HTA and economic
evaluations of the cost-effectiveness of alternative AK treatments
available in Europe. However, there are some limitations of this
NMA for clinical practice and policymaking. Firstly, some
treatment options for AK could not be included in the NMA
because they could not be linked in the treatment network, such as
colchicine and resiquimod. Secondly, in clinical practice some
treatment courses may be repeated, such as 5-FU and DFC, but
this could not be studied in the NMA as no RCT’s studied this.
Finally, recurrence of cleared lesions may occur. Observational
long-term recurrence data is available for some treatments but
Figure 3. Absolute clearance rates (bars ± SE; left axis) and ranking according to the probability to be the best treatment (yellow
dots; right axis) and the SUCRA score (yellow squares; right axis).
doi:10.1371/journal.pone.0096829.g003
Table 3. Efficacy of AK treatments for total patient clearance.
OR for total patient clearance Treatment ranking
Direct meta-analysis Network meta-analysis Probability to be best SUCRA
Placebo 1 (reference) 1 (reference) 0.0% 0.0%
MAL-PDT 14.3 (7.1–28.6) 16.5 (6.5–42.1) 1.1% 57.2%
BF-200 ALA 40.1 (16.1–100.1) 45.9 (13.9–151.8) 64.8% 92.1%
ALA-PDT patch 16.7 (7.3–38.2) 18.1 (5.6–58.9) 6.7% 62.8%
Cryotherapy 7.3 (2.7–19.4) 8.0 (2.4–26.9) 0.3% 30.6%
Imiquimod 5% (16 weeks) 21.7 (10.9–42.9) 23.8 (10.4–54.2) 10.1% 74.2%
Imiquimod 5% (4 weeks) 17.5 (2.4–128.3) 17.6 (6.5–47.6) 3.9% 60.9%
Diclofenac 3% 3.4 (2.3–4.9) 4.3 (2.1–8.6) 0.0% 14.0%
5-FU 0.5% 20.5 (4.2–100.5) 20.7 (7.7–55.7) 7.2% 66.8%
Ingenol mebutate 16.8 (9.2–30.8) 16.4 (5.0–53.6) 5.5% 58.1%
Imiquimod 3.75% (4 weeks) 8.5 (5.1–14.3) 8.7 (2.9–26.2) 0.6% 33.2%
doi:10.1371/journal.pone.0096829.t003
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these could not be included in a NMA that focuses on RCT
evidence as the evidence base for recurrence is limited in RCTs. A
recent study has compared recurrences and probabilities for
patients to be still cleared after one year for several treatment
modalities that are also reviewed here [52]. Our analysis did not
take differences in adverse events, cosmetic outcomes and
treatment costs into consideration which may also have to be
considered in the context of decision-making. However, results
from this NMA may provide relative efficacy data to inform future
cost-effectiveness studies of AK treatments used in clinical practice
in Europe.
Conclusions
The results from this NMA of available treatments in AK
suggest that BF-200 ALA gel, using narrow-band lights, is
expected to provide the greatest response in terms of complete
patient clearance of AKs on the face and scalp. The NMA ranked
BF-200 ALA with the highest probability of being the most
efficacious treatment for this outcome measure. This study extends
on the recent study of Gupta et al which was also based on the
Cochrane review but did not distinguish between alternative PDT
agents. Our NMA therefore is relevant for clinical and HTA based
decision-making, and can assist in the improved management of
AK.
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